Clinical Trial Update: Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating capecitabine with temozolomide and radiolabeled peptide therapy (Lutetium-177) for midgut and pancreatic neuroendocrine tum…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Midgut Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Capecitabine (capecitabine)
• Lutetium-177 - radiolabeled peptide therapy (Octreotate) (Lutetium-177 octreotate radioligand therapy)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Australasian Gastro-Intestinal Trials Group | Conditions: Midgut Neuroendocrine Tumours, Pancreatic Neuroendocrine Tumours | Phase 2 | Status: COMPLETED